Thomas Powles, MBBS, MRCP, MD
McDermott DF et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24(6):749-57. Abstract
Motzer RJ et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103-15. Abstract
Motzer RJ et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277-90. Abstract
Powles T et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): Phase III KEYNOTE-426 study. Genitourinary Cancers Symposium 2019;Abstract 543.
Rini BI et al. Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. ASCO 2019;Abstract 4512.
Tannir NM et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). Genitourinary Cancers Symposium 2019;Abstract 547.
Toni K Choueiri, MD
Cella D et al. Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs everolimus (EVE) in the phase III CheckMate 025 study. ASCO 2016;Abstract 4549.
Choueiri TK et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17(7):917-27. Abstract
Escudier B et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. J Clin Oncol 2018;36(8):765-72. Abstract
Hutson TE et al. Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN + EVE in metastatic renal cell carcinoma (mRCC). ASCO 2016;Abstract 4553.
Motzer RJ et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473-82. Abstract
Motzer RJ et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803-13. Abstract
Powles T et al. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 2018;119(6):663-9. Abstract
Rini BI et al. TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Genitourinary Cancers Symposium 2019;Abstract 541.
Vaishampayan U et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: Phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer 2019;7(1):275. Abstract
Thomas E Huston, DO, PharmD
Escudier B et al. Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC). Genitourinary Cancers Symposium 2018;Abstract 618.
Gabrilovich DI et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2(10):1096-103. Abstract
Goel S et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91(3):1071-121. Abstract
Loo V et al. First-line systemic therapy for metastatic clear-cell renal cell carcinoma: Critical appraisal of emerging options. Target Oncol 2019;14(6):639-645. Abstract
Oyama T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160(3):1224-32. Abstract
Rini BI et al; IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomized controlled trial. Lancet 2019;393(10189):2404-15. Abstract
Taylor MH et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020;[Epub ahead of print]. Abstract
David F McDermott, MD
Amos SM et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011;118(3):499-509. Abstract
Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714-68. Abstract
Cella D et al. Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial. ASCO 2018;Abstract 3073.
Motzer RJ et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). ESMO 2018;Abstract LBA6_PR.
Motzer RJ et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277-90. Abstract
Motzer RJ et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803-13. Abstract
Nakajima EC et al. Challenge of rechallenge: When to resume immunotherapy following an immune-related adverse event. J Clin Oncol 2019;37(30):2714-8. Abstract
Rini BI et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116-27. Abstract
Tannir NM et al. Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N + I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214. Genitourinary Cancers Symposium 2019;Abstract 581.
Tannir NM et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). Genitourinary Cancers Symposium 2019;Abstract 547.
Weber JS et al. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30(21):2691-7. Abstract